Europe

Wed
20
Mar

British study links high potency cannabis to psychosis

A study published on Tuesday in British medical journal, the Lancet Psychiatry, states that high potency cannabis or heavy use of cannabis can induce psychosis and can be harmful for mental health.

Dr. Marta Di Forti, lead author of study and clinician scientist at the Institute of Psychiatry, Psychology & Neuroscience, King’s College London, said that psychotic disorder was specifically studied.

The researchers examined data from 11 different sites that treat psychosis – 10 across Europe and one in Brazil. They looked at 901 patients who had a first-time episode of psychosis over five years and compared them to more than 1,237 matched non-patients.  

Fri
15
Mar

An interview with Dinafem Seeds: Europe’s king of feminized seeds

The evolution of cannabis genetics around the world is at a pinnacle. And with many advancements in breeding projects, the technology to produce feminized seed is now a reality. Producing top quality seeds is easier said than done, however. High Times sat down with Professor OG (not his real name) from Dinafem Seeds, a renowned European seed bank best known for their feminized, auto-flowering, and CBD seeds, and talked to them about breeding projects, working with CBD lines, upcoming releases, and how popular feminized seeds are across the pond.

Thu
14
Mar

Euro stakeholders upbeat on reversing CBD-in-food rule changes

European hemp stakeholders came away upbeat from a meeting with European Commission officials yesterday as they seek to reverse recent food rule changes that could upend the hemp food business across the continent.

“We launched a good dialogue for sound negotiations with the Commission and Member States today,” Lorenza Romanese, Managing Director of the European Industrial Hemp Association (EIHA) told HempToday after the meeting with a working group of the EC’s Standing Committee on Plants, Animals, Food and Feed (PAFF). “We have something to work on together.”

Wed
13
Mar

Aurora Cannabis strikes oil in Germany, and higher revenue and profit margins should be on the way

Nearly everyone has focused on Aurora Cannabis' (NYSE:ACB) great opportunity in the Canadian recreational marijuana market. The company has gotten off to a pretty good start with that opportunity, capturing a 20% market share in its latest quarter.

But nearly everyone also knows that Aurora's future rides largely on international medical marijuana markets. The largest of these international opportunities right now is Germany. On Tuesday, Aurora Cannabis announced that it had begun selling cannabis oils to German pharmacies. It's a milestone that should mean that higher revenue and profit margins are on the way. 

Mon
11
Mar

CBD Ban: Brits take up fight and send lawyers to Brussels

Cannabis lawyers are heading to Brussels next week to challenge a recent decision by the European Union to reclassify food products containing cannabidiol (CBD) and prohibit their sale.

While the rest of the western world moves towards acceptance of cannabis products either medically or recreationally, the European Union pushed back in February, updating a classification of CBD under the Novel Food Regulation.

The law ((EU) 2015/2283), which applies across all member states, means any product deemed as ‘novel’ must gain authorization from food authorities before it can be sold as a foodstuff within the EU.  Food can be considered ‘novel’ if it was not consumed by humans to any significant degree prior to May 1997.

Tue
05
Mar

Bankers are circling Europe’s growing cannabis market

Investors who are eager for the cannabis industry in Europe to emulate the boom in pot-stock listings in Canada may not have much longer to wait, judging by the activities of investment bankers.

 

Canaccord Genuity Inc., the biggest underwriter of stock offerings for weed-related companies, has appointed a head of European cannabis investment banking. French bank Bryan Garnier & Co. in the past year started covering the Canadian sector via a Paris-based analyst. Jefferies Financial Group Inc. recently initiated coverage on a slew of North American pot stocks through a London-based analyst.

Sun
17
Feb

European Parliament approves bill that would incentivize countries to allow medical marijuana

Recently the World Health Organization recommended that countries around the world reschedule marijuana and remove it from international drug treaties. And now the European Parliament is doing the same, Joseph Misulonas.

Fri
15
Feb

Will Aurora Cannabis continue bleeding money in 2019?

Aurora Cannabis (NYSE:ACB) lost a frightening amount of money during the last three months of 2018 and investors are justifiably concerned about more losses ahead. Despite posting heavy losses, management expects a sales explosion before the end of 2019 that could allow this giant Canadian cannabis producer to begin posting a profit by the end of the year.

Should investors brace for further losses ahead, or will Aurora Cannabis find a way to make ends meet before the end of 2019? Here's what you need to know to decide for yourself.

Mon
11
Feb

These three medical cannabis companies are growing larger across the globe

Portuguese company Holigen is looking to build one of the largest cannabis cultivation facilities in the world in the Alentejo region of Portugal. The site will house 500,000 kilograms of cannabis per year to start.

According to the company, the warm climate and low labor costs make Portugal an ideal place to grow cannabis.

When it is fully operational in 2020, Holigen claims the facility will be capable of producing 635,000 kilograms per year. It’s a harvest that would place Holigen among the world’s top cannabis producers.

In August 2018, Holigen acquired a 5,000-square-meter site in Lisbon. In September, the company did its first non-founder capital raise to begin building the biggest indoor, and outdoor licensed medical cannabis grow in Europe.

Thu
31
Jan

Harvest One launches Satipharm reformulated CBD capsules in Europe

Harvest One Cannabis Inc. reports the company’s wholly owned medical subsidiary, Satipharm Ltd., has launched European sales of its recently reformulated CBD capsules.

“The first product to market is the Satipharm 10 mg CBD Gelpell® capsule that provides superior bioavailability and quality,” notes a press release from Harvest One, a global cannabis company that develops and provides lifestyle and wellness products to consumers and patients in regulated markets around the world. They are currently available online at www.satipharm.com.

Pages

Subscribe to RSS - Europe